Vaxcyte Inc

Vaxcyte has raised roughly US$1b through concurrent common stock, pre funded warrant and convertible note offerings, following positive Phase 3 data for its VAX 31 pneumococcal vaccine candidate. The financing came after the Phase 3 OPUS 1 readout, and the company's shares have traded at US$66.96, with a 7 day share price return of 17.68% and a year to date share price gain of 44.12%. The 1 year total shareholder return of 64.36% and 5 year total shareholder return of 175.56% reflect momentum reinforced by the OPUS 1 update and the US$1b mix of equity and convertible note financing completed this week. Vaxcyte is currently trading at 3.6x book value, compared with 2x for the wider US Biotechs group and 9.3x for closer peers, while a widely followed narrative framework anchors fair value closer to $75 using a 7.51% discount rate. Completion of a dedicated large scale manufacturing facility with Lonza, build out of a high volume fill finish line in North Carolina and plans to build commercial supply ahead of a possible VAX-31 launch could support stronger net margins, though OPUS-2 or OPUS-3 data or higher than modeled manufacturing costs could reset expectations.

Vaxcyte has priced concurrent underwritten public offerings consisting of $500M in equity and $500M in 1.50% convertible senior notes due 2032, for total expected aggregate gross proceeds of $1B. The equity portion comprises 7.41M shares of common stock priced at $64.00 per share, along with pre-funded warrants to purchase 400K common shares at $63.999 per warrant, with an exercise price of $0.001 per share, and underwriters were granted a 30-day option to purchase up to an additional 1.17M common shares at the public offering price. The senior, unsecured notes carry an annual interest rate of 1.50%, payable semi-annually on April 15 and October 15 starting April 15, 2027, and mature on October 15, 2032, unless earlier repurchased, redeemed, or converted, with an initial conversion rate of 11.1607 shares per $1,000 principal amount, representing an initial conversion price of approximately $89.60 per share, a 40.0% premium over the public equity offering price. Underwriters hold a 30-day option to purchase up to an additional $75M in aggregate principal amount of notes. Vaxcyte plans to deploy the proceeds toward clinical development of its VAX-31 pneumococcal conjugate vaccine candidate in adult and pediatric populations, including the Phase 3 OPUS-2 influenza co-administration trial, the OPUS-3 prior pneumococcal vaccination trial, manufacturing consistency studies, and Phase 2 infant dose-finding studies, as well as manufacturing scale-up, inventory expansion, and global capacity buildout ahead of a potential U.S. adult commercial launch. Both offerings are scheduled to close on October 9, 2026, subject to customary closing conditions, and neither offering is contingent upon the completion of the other.

Vaxcyte shares jumped about 32% in Monday morning trading after the company reported positive phase 3 topline data for VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. The OPUS-1 trial tested non-inferiority and immunogenicity of VAX-31 against Merck's Capvaxive and Pfizer's Prevnar 20 in patients aged 50 and over. For the 11 serotypes shared by the three shots, VAX-31 met all primary noninferiority assessments, and three serotypes unique to VAX-31 plus cross-reactive serotype 20B met the OPA GMR superiority criterion. Vaxcyte plans to release results from two other phase 3 trials, OPUS-2 and OPUS-3, in the first half of 2027, with a BLA eyed for the first half of 2028. Approved vaccines cover significantly fewer pneumonia strains than VAX-31: Capvaxive covers 21 strains and Prevnar 20 covers 20.

Vaxcyte announced two C-suite hires on September 3 and narrowed the timeline for its most important catalyst, saying it now expects topline safety, tolerability and immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 trial by the end of October rather than sometime in the fourth quarter. Luis Jodar joins as Chief Medical Officer after 17 years at Pfizer, where he was Chief Medical Officer for Vaccines and Infectious Diseases and helped lead clinical development and medical affairs for Prevnar 13 and Prevnar 20, the pneumococcal vaccines VAX-31 is trying to displace. David McAvoy joins as Chief Legal Officer from Teva Pharmaceutical, where he ran a 235-person legal, compliance and government affairs organization as Executive Vice President and Chief Legal Officer, and previously served as General Counsel of Endocyte through its $2.1 billion acquisition by Novartis and spent 27 years at Eli Lilly. The OPUS-1 trial alone dosed 4,049 participants in a head-to-head comparison against Prevnar 20 and Capvaxive, part of a broader Phase 3 program that has dosed 6,191 adults in total, roughly 3,500 of them with VAX-31, and Vaxcyte held about $2.5 billion in cash, cash equivalents and investments as of June 30, 2026. The trial measures safety, tolerability and immunogenicity against Prevnar 20 and Capvaxive rather than a fresh efficacy claim, so the near-term thesis rests on VAX-31 clearing a noninferiority bar, and the company still has no approved product or product revenue, with OPUS-2 and OPUS-3 data and the VAX-31 infant Phase 2 study not expected until the first half of 2027 and the VAX-A1 Group A Strep candidate not guided to topline data until the second half of 2027.

Vaxcyte expects to report topline results from its pivotal Phase 3 OPUS-1 trial of the pneumococcal vaccine candidate VAX-31 by the end of October, narrowing its previous guidance for a fourth-quarter readout. The OPUS-1 study, which is part of a three-trial adult program involving 6,191 participants, will provide safety, tolerability, and immunogenicity data from a noninferiority study in adults. The company also appointed former Pfizer vaccine executive Luis Jodar as chief medical officer and David McAvoy, formerly of Teva Pharmaceutical Industries, as chief legal officer, as it prepares for a potential Biologics License Application and commercial launch. VAX-31 is the broadest-spectrum pneumococcal conjugate vaccine in clinical development, designed to protect against 31 bacterial serotypes, and results from the other two trials, OPUS-2 and OPUS-3, are expected in the first half of 2027.

Vaxcyte Inc. is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 18, Mizuho Securities analyst Salim Syed reiterated a Buy rating on Vaxcyte Inc. with a price target of $163, reflecting a significant 180% upside from current levels. Earlier on June 16, the company announced an update regarding its ongoing early-stage clinical trial of VAX-A1, a vaccine designed to protect against Group A strep infections. The study will evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy young adults, testing three different dose levels against a placebo. If the trial shows positive results, the vaccine could allow the company to enter a new market for preventing Group A strep infections, potentially boosting investor confidence and supporting the stock's valuation.

Vaxcyte has dosed the first participant in its Phase 1 first-in-human clinical trial of VAX-A1, an experimental vaccine against Group A Streptococcus, a disease for which no approved vaccine currently exists. The trial will enroll 80 healthy adults aged 18 to 40 in Australia, a country with high rates of Group A Strep disease and established research networks. The study is structured in two stages, with an initial safety checkpoint after 12 participants before expanding to the full cohort. All participants will receive two doses of VAX-A1 or a placebo spaced about two months apart and will be monitored for six months after the final dose, testing low, mid, and high dose levels to balance immune response and tolerability. Vaxcyte estimates that Group A Strep causes 800 million illnesses globally each year, ranging from strep throat to life-threatening infections and rheumatic heart disease.